FibroBiologics (FBLG) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
FibroBiologics is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | KYNB |
|---|---|---|
| Share price | $0.705 | $1.56 |
| Market cap | $6.34M | $6.32M |
| 1-day change | -15.06% | -13.33% |
| YTD return | — | -82.23% |
| 1-year return | — | -81.47% |
| 5-year return | — | -99.49% |
| EPS (TTM) | $-2.51 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.44M |
| Revenue growth (YoY) | — | -78.26% |
| Net income (latest FY) | $-18.65M | $183.45M |
| Gross margin | — | 91.37% |
| Operating margin | — | -712.66% |
| Net margin | — | 2848.63% |
| 52-week high | $9.60 | $10.47 |
| 52-week low | $0.62 | $1.56 |
| Distance from 52-week high | -92.66% | -85.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +1673.05% | +2442.95% |
| Average volume | 160.05K | 29.96K |
| Shares outstanding | 8.99M | 4.05M |
| Employees | 15 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
FBLG vs KYNB FAQ
Which is bigger, FibroBiologics or Kyntra Bio?
FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.32M for Kyntra Bio (KYNB).
Are FibroBiologics and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.